Inhibrx Biosciences Inc. (INBX) vs Omeros Corporation (OMER)
A side-by-side comparison of Inhibrx Biosciences Inc. and Omeros Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
INBX
Inhibrx Biosciences Inc.
$95.17HealthcareDelayed quote: Oct 6, 2026, 1:05 PM EDT
OMER
Omeros Corporation
$18.52HealthcareDelayed quote: Oct 6, 2026, 1:05 PM EDT
Total return — INBX vs OMER
growth of $100 · dividends reinvested · last 6yINBX +382.3% (+30.0%/yr)OMER +43.3% (+6.2%/yr)INBX compounded faster over this window
INBX OMER
INBX vs OMER: by the numbers
- •INBX is the larger company ($1.40B vs $1.34B market cap).
- •OMER is profitable (324.88% net margin) while INBX runs a net loss (-10773.46%).
Metrics side by side
Valuation
| Metric | INBX | OMER |
|---|---|---|
| P/E ratio | N/A | 10.77 |
| Forward P/E | N/A | 20.43 |
| P/S ratio | N/A | 34.89 |
Profitability
| Metric | INBX | OMER |
|---|---|---|
| Gross margin | -91.00% | 0.00% |
| Operating margin | -10386.54% | 0.00% |
| Net margin | -10773.46% | 324.88% |
| ROIC | -99.35% | -32.06% |
Growth (annualized)
| Metric | INBX | OMER |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 0.90% |
| Total return CAGR (5Y) | 27.64% | 21.70% |
Frequently asked
- Is INBX or OMER more profitable?
- OMER runs the higher net margin — INBX at -10773.46% versus OMER at 324.88%.
- How have INBX and OMER total returns compared?
- Over the past 5 years, INBX delivered 27.64% and OMER delivered 21.70% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Omeros P/E ratioInhibrx Biosciences ROEOmeros ROEInhibrx Biosciences operating marginOmeros operating marginInhibrx Biosciences revenue growthOmeros revenue growthInhibrx Biosciences free cash flowOmeros free cash flow
Inhibrx Biosciences & Omeros appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.